revumenib
AssetAlso called SNDX-50613 FREE BASE, SNDX-5613 Free Base, Revuforj
Inhibits menin to disrupt oncogenic transcription driven by KMT2A rearrangements.
- Stage
- Approved
- Modality
- Small molecule
- Target
- KMT2A
- 17
- Indications
- 26
- Trials
- 1
- Developer
Approved by the FDA on Nov 15, 2024 (NDA218944). FDA
Indications
17Relapsed or refractory acute leukemia with a KMT2A translocation
Approved, FDA
Refractory Acute Leukemia
Approved, FDA
Relapsed or refractory acute myeloid leukemia
Approved, FDA
14 more
In the full profile
- Target and mechanism2
- Owner and partners1
- Trials26
- Evidence for its targets2
- Competitors12
- Aging relevance1
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.